ClinicalTrials.gg
CompletedNCT06857695Updated May 28, 2025

A Study to Assess the Mass Balance and ADME of [14C]AZD5004 and the Absolute Bioavailability of AZD5004

A Phase 1 interventional study of AZD5004 film-coated tablet and [14C]AZD5004 Solution for Infusion in Healthy Participants, sponsored by AstraZeneca. Completed at 1 site in United Kingdom. Open to male participants aged 30 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-28.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
30 Years to 65 Years
Sex
Male
01

Study summary

This study in healthy volunteers aims to answer these questions:

  • Does the test medicine cause any important side effects?
  • What are the blood levels of the test medicine and how quickly does the body get rid of it?
  • How much of the test medicine taken by mouth gets into the bloodstream?
  • How does the body break down and get rid of the test medicine?

This study will take place at one site in Nottingham, United Kingdom, and plans to enrol 8 healthy men aged 30-65 years, who will be involved in both parts of the study.

Read the detailed description

In this 2-part study, healthy volunteers will be given three doses of test medicine to find out how the body breaks down and gets rid of the test medicine. Two doses will be 'radiolabelled' - they will contain a small amount of radioactivity (Carbon-14) so that it can be tracked in the body. The amount of radiactivity is less than 6 days of the average radiation exposure received in the UK each year, and slightly less than the radiation dose that would result from a single head x-ray or two leg x-rays.

This study in healthy volunteers aims to answer these questions:

  • Does the test medicine cause any important side effects?
  • What are the blood levels of the test medicine and how quickly does the body get rid of it?
  • How much of the test medicine taken by mouth gets into the bloodstream?
  • How does the body break down and get rid of the test medicine?

This study will take place at one site in Nottingham, United Kingdom.

It plans to enrol 8 healthy men aged 30-65 years, who will be involved in both parts of the study.

In Part 1, volunteers will receive a single dose of the test medicine by mouth and, on the same day, a very tiny dose of radiolabelled study medicine by injection into a vein. After a minimum of 7 days, in Part 2, volunteers will receive a dose of test medicine containing a very tiny amount of radio label, by mouth. They'll stay in the clinic for up to 6 nights in Part 1 and 8 nights in Part 2 and take up to 7 weeks to finish the study.

We'll collect blood and urine samples to do safety tests. Over a period of at least 15 days, we'll take many blood samples. In Part 2 volunteers will collect all their urine and faeces so that we can measure the amount of test medicine and its breakdown products.

02

Conditions studied

  • Healthy Participants

Keywords

  • Healthy Participants
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males aged 30 to 65 years inclusive
  • in the range 18.0 - 35.0 kg/m2 and body weight ≥63 kg
  • Regular bowel movements (i.e. average stool production of ≥1 and ≤3 stools per day)

Exclusion criteria

Exclusion Criteria:

  • History of any disease or disorder
  • History or presence of clinically significant gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs
  • History of severe allergy/ or ongoing allergy/hypersensitivity
  • Excessive intake of caffeine containing drinks or food
  • History/family history of medullary thyroid carcinoma or multiple endocrine neoplasia
  • Uncontrolled thyroid disease
  • History of acute pancreatitis or gallstones
  • Serum triglyceride concentrations > 1000 mg/dL (11 mmol/L)
  • Any history of significant inflammatory bowel disease, gastroparesis, or other severe disease or prior surgery affecting the upper GI tract
  • Participants who do not have suitable veins for multiple venepunctures/cannulation
  • Clinically significant abnormal clinical chemistry, haematology or urinalysis
  • Significant hepatic disease
  • Any clinically significant abnormalities in rhythm, conduction, or morphology of the resting and any clinically important abnormalities in the 12-lead ECG
  • Abnormal renal function
  • Radiation exposure exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years, occupationally exposed worker, or have been administered IMP in a [14C] ADME study in the last 12 months.
  • Use of any prescribed or non-prescribed medication
  • Current smokers or known or suspected history of alcohol or drug abuse.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    AZD5004

    A single dose of AZD5004 film-coated tablet and a single dose of \[14C\]AZD5004 Solution for Infusion (Part 1) A single dose of \[14C\]AZD5004 Oral Solution (Part 2)

    Drug: AZD5004 film-coated tablet · Drug: [14C]AZD5004 Solution for Infusion · Drug: [14C]AZD5004 Oral Solution

Interventions

06

What researchers measure

Primary outcomes

  1. Absolute bioavailability - Part 1

    Absolute bioavailability (F) based on AUC0-inf of oral and IV administration, adjusted for dose

    Time frame: Plasma sample collection from pre-dose to 110 hrs post-dose

  2. Amount of AZD5004 excreted (Ae) - Part 2

    Mass balance recovery of total radioactivity (TR) in urine, faeces and all excreta (urine and faeces combined)

    Time frame: Urine and faecal samples collected from pre-dose until 168 hours post-dose

  3. Amount of AZD5004 excreted expressed as a percentage of the dose administered (Fe) - Part 2

    Mass balance recovery of total radioactivity (TR) in urine, faeces and all excreta (urine and faeces combined)

    Time frame: Urine and faecal samples collected from pre-dose until 168 hours post dose

  4. Cumulative amount of AZD5004 excreted (CumAe) - Part 2

    Mass balance recovery of total radioactivity (TR) in urine, faeces and all excreta (urine and faeces combined)

    Time frame: Urine and faecal samples collected from pre-dose until 168 hours post dose

  5. Cumulative amount of AZD5004 excreted expressed as a percentage of the dose administered (CumFe) - Part 2

    Mass balance recovery of total radioactivity (TR) in urine, faeces and all excreta (urine and faeces combined)

    Time frame: Urine and faecal samples collected from pre-dose until 168 hours post dose

Secondary outcomes

  1. Maximum observed concentration (Cmax) for AZD5004 and total radioactivity (TR) - Part 1 and Part 2

    Pharmacokinetics (PK) ofAZD5004 and \[14C\]AZD5004 in plasma

    Time frame: Plasma sample collection from pre-dose to 110 hours post-dose in Part 1 and from pre-dose to 168 hours post-dose in Part 2

  2. Area under the curve from time 0 extrapolated to infinity (AUC0-inf) for AZD5004 - Part 1 and Part 2

    Pharmacokinetics (PK) of AZD5004 and \[14C\]AZD5004 in plasma

    Time frame: Plasma sample collection from pre-dose to 110 hours post-dose in Part 1 and from pre-dose to 168 hours post-dose in Part 2

  3. Area under the curve (AUC) of circulating plasma total radioactivity (TR) or accounting for 10% or more of the dose in excreta - Part 2

    Identification of the chemical structure of each metabolite accounting for more than 10% by AUC of circulating total radioactivity (TR) or accounting for 10% or more of the dose in excreta

    Time frame: Plasma, urine and faecal samples from pre-dose until 168 hours post-dose

  4. Blood:plasma concentration ratios - Part 2

    Blood:plasma concentration ratios for total radioactivity (TR)

    Time frame: Whole blood and plasma samples collected from pre-dose until 168 hoours post-dose

  5. Number of subjects with treatment-related adverse events - Part 1 and 2

    To provide additional safety and tolerability information for AZD5004 by assessing the incidence of AEs

    Time frame: Through study duration, approximately 7 weeks

07

Study locations

1 site
  • Research Site
    Ruddington, NG11 6JS, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual participant-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual participant-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2025 to primary completion in May 2025, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2025
First posted
Mar 4, 2025
StartActual
Mar 6, 2025
Primary completionActual
May 5, 2025
CompletionActual
May 5, 2025
Last update
May 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06857695
Lead sponsor
AstraZeneca
Collaborators
Quotient Sciences
Responsible party
Sponsor
First posted
Mar 4, 2025
Start date
Mar 6, 2025
Primary completion
May 5, 2025
Completion
May 5, 2025
Last update
May 28, 2025

Study contacts

Sharan Sidhu, MBChB, BAO, MRCS, MFPM
principal investigator · Quotient Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elecoglipron

Start the discussion